Index S&P 500 P/E 65.98 EPS (ttm) 0.98 Insider Own 1.15% Shs Outstand 157.92M Perf Week -2.77%
Market Cap 10.26B Forward P/E 29.73 EPS next Y 2.18 Insider Trans -0.83% Shs Float 156.27M Perf Month -17.52%
Income 158.11M PEG 5.15 EPS next Q 0.51 Inst Own 100.11% Short Float 2.53% Perf Quarter -2.90%
Sales 1.20B P/S 8.58 EPS this Y 7.25% Inst Trans 1.05% Short Ratio 3.73 Perf Half Y -10.26%
Book/sh 13.16 P/B 4.93 EPS next Y 15.04% ROA 5.85% Short Interest 3.95M Perf Year -7.69%
Cash/sh 1.12 P/C 57.80 EPS next 5Y 12.81% ROE 7.82% 52W Range 61.16 - 85.57 Perf YTD -9.87%
Dividend Est. 0.26 (0.39%) P/FCF 40.36 EPS past 5Y 11.13% ROI 6.43% 52W High -24.13% Beta 1.27
Dividend TTM 0.32 (0.49%) Quick Ratio 2.77 Sales past 5Y 10.61% Gross Margin 66.44% 52W Low 6.15% ATR (14) 2.76
Dividend Ex-Date Feb 14, 2025 Current Ratio 3.94 EPS Y/Y TTM -29.62% Oper. Margin 21.42% RSI (14) 29.96 Volatility 3.37% 3.96%
Employees 3100 Debt/Eq 0.19 Sales Y/Y TTM 4.46% Profit Margin 13.22% Recom 1.82 Target Price 85.75
Option/Short Yes / Yes LT Debt/Eq 0.18 EPS Q/Q 26.57% Payout 30.61% Rel Volume 1.87 Prev Close 65.49
Sales Surprise 3.94% EPS Surprise 8.75% Sales Q/Q 8.96% Earnings Feb 05 BMO Avg Volume 1.06M Price 64.92
SMA20 -8.16% SMA50 -11.23% SMA200 -13.11% Trades
Volume 1,973,051 Change -0.87%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-19-25 Downgrade Robert W. Baird
Outperform → Neutral
$88 → $68
May-22-24 Downgrade Citigroup
Buy → Neutral
$85
Feb-08-24 Initiated Scotiabank
Sector Outperform
$80
Feb-02-24 Downgrade Stifel
Buy → Hold
$65
Dec-07-23 Initiated UBS
Buy
$80
Aug-28-23 Initiated William Blair
Outperform
Jan-10-23 Upgrade Wells Fargo
Underweight → Equal Weight
$90
Dec-14-22 Initiated Deutsche Bank
Buy
$100
Dec-12-22 Upgrade Citigroup
Neutral → Buy
$81.25 → $100
Dec-07-22 Initiated RBC Capital Mkts
Sector Perform
$89
Aug-25-22 Initiated Credit Suisse
Outperform
$465
Apr-25-22 Downgrade Wells Fargo
Equal Weight → Underweight
$370
Sep-15-21 Upgrade KeyBanc Capital Markets
Sector Weight → Overweight
$600
Mar-08-21 Upgrade Stephens
Equal-Weight → Overweight
$380 → $425
Feb-23-21 Upgrade Stifel
Hold → Buy
$435
Jan-25-21 Reiterated The Benchmark Company
Buy
$320 → $410
Nov-10-20 Initiated KeyBanc Capital Markets
Sector Weight
$340
Sep-30-20 Initiated Atlantic Equities
Overweight
$365
Jul-15-20 Downgrade Stephens
Overweight → Equal-Weight
May-27-20 Downgrade Stifel
Buy → Hold
$245 → $260
Show Previous Ratings
Feb-20-25 07:00AM
Feb-18-25 07:00AM
Feb-10-25 07:19PM
Feb-06-25 02:09AM
12:40AM
(Thomson Reuters StreetEvents)
08:18PM
Loading…
Feb-05-25 08:18PM
08:13AM
06:41AM
06:30AM
06:30AM
Feb-04-25 07:00AM
Jan-21-25 07:00AM
07:00AM
Jan-10-25 07:00AM
07:00AM
07:00AM
Loading…
Jan-08-25 07:00AM
07:00AM
Jan-07-25 07:00AM
Dec-20-24 07:00AM
Dec-19-24 07:00AM
Dec-18-24 07:00AM
Dec-12-24 07:00AM
Dec-10-24 07:00AM
Dec-09-24 07:33PM
Nov-29-24 11:32AM
Nov-27-24 07:00AM
Nov-25-24 09:02AM
Nov-22-24 09:00AM
Nov-20-24 07:00AM
Nov-18-24 07:00AM
06:58PM
Loading…
Nov-15-24 06:58PM
(Morningstar Research) -6.85%
Nov-14-24 07:00AM
Nov-11-24 05:47PM
07:00AM
Nov-08-24 07:00AM
Nov-07-24 07:00AM
Nov-06-24 07:00AM
12:05AM
Nov-05-24 06:51PM
07:00AM
Oct-31-24 10:39AM
03:08AM
01:01AM
(Thomson Reuters StreetEvents)
Oct-30-24 06:30AM
06:30AM
Oct-29-24 07:00AM
Oct-17-24 06:57PM
Oct-10-24 07:00AM
Oct-09-24 08:00AM
07:00AM
Oct-08-24 04:25PM
07:00AM
Oct-07-24 07:00AM
Oct-03-24 05:34PM
Sep-26-24 07:00AM
Sep-24-24 07:00AM
Sep-19-24 06:37PM
(Morningstar Research) +5.03%
Sep-18-24 07:00AM
07:00AM
Sep-17-24 07:00AM
07:00AM
Sep-16-24 07:00AM
Sep-09-24 05:11AM
Aug-27-24 07:00AM
Aug-26-24 07:00AM
Aug-23-24 01:04AM
Aug-08-24 02:28PM
Aug-07-24 07:20PM
(Morningstar Research) -9.51%
06:30AM
06:30AM
Jul-31-24 07:00AM
Jul-29-24 07:00AM
Jul-15-24 07:00AM
Jul-12-24 06:58PM
Jul-09-24 06:00AM
Jul-02-24 07:06PM
May-31-24 07:00AM
May-30-24 07:00AM
May-29-24 07:00AM
May-23-24 10:26AM
07:00AM
May-22-24 07:00AM
May-20-24 01:34PM
May-14-24 04:49AM
May-08-24 07:00AM
May-07-24 07:00AM
May-06-24 05:57AM
May-02-24 11:40AM
11:31AM
10:49AM
10:34AM
08:17AM
08:00AM
03:11AM
May-01-24 04:54PM
02:05PM
01:52PM
12:08PM
11:10AM
09:30AM
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Herr Amy E. Director Feb 14 '25 Option Exercise 44.33 1,976 87,596 3,836 Feb 18 04:49 PM Herr Amy E. Director Feb 14 '25 Sale 65.96 1,860 122,691 1,976 Feb 18 04:49 PM JOSHUA MOLHO Domestic Partner of Director Feb 14 '25 Proposed Sale 65.96 1,860 122,691 Feb 14 04:08 PM McManus Matthew President - DGS Feb 01 '25 Option Exercise 0.00 4,620 0 4,620 Feb 04 05:31 PM Geist William PRESIDENT, PROTEIN SCIENCES Feb 01 '25 Option Exercise 0.00 3,320 0 14,401 Feb 04 05:27 PM Kelderman Kim Chief Executive Officer Jan 27 '25 Option Exercise 37.70 13,392 504,878 52,396 Jan 29 04:35 PM Kelderman Kim Chief Executive Officer Jan 27 '25 Sale 77.29 13,392 1,035,013 39,004 Jan 29 04:35 PM KIM KELDERMAN Director Jan 27 '25 Proposed Sale 77.05 13,392 1,031,854 Jan 27 04:24 PM Geist William PRESIDENT, PROTEIN SCIENCES Nov 01 '24 Option Exercise 0.00 9,912 0 14,351 Nov 05 04:48 PM Hippel James CFO Nov 01 '24 Option Exercise 0.00 13,159 0 113,085 Nov 05 04:46 PM HIGGINS JOHN L Director Sep 12 '24 Option Exercise 22.95 6,000 137,700 48,608 Sep 16 04:18 PM Kelderman Kim Chief Executive Officer Aug 29 '24 Option Exercise 66.97 1,492 99,919 41,434 Sep 03 04:05 PM Bohnen Shane SVP - General Counsel Aug 15 '24 Option Exercise 0.00 49 0 1,696 Aug 19 05:28 PM BAUMGARTNER ROBERT V Director Aug 08 '24 Option Exercise 22.95 16,000 367,200 59,401 Aug 12 04:08 PM BAUMGARTNER ROBERT V Director Aug 08 '24 Sale 72.10 16,000 1,153,664 43,401 Aug 12 04:08 PM ROBERT V. BAUMGARTNER Director Aug 08 '24 Proposed Sale 72.10 16,000 1,153,664 Aug 08 04:13 PM Hippel James CFO Aug 02 '24 Option Exercise 31.26 53,000 1,656,780 136,002 Aug 06 04:23 PM Kelderman Kim Chief Executive Officer Jul 31 '24 Option Exercise 37.70 14,000 527,800 49,421 Aug 02 04:17 PM Hippel James CFO Jul 23 '24 Option Exercise 31.26 35,000 1,094,100 107,284 Jul 25 04:31 PM HIGGINS JOHN L Director Jul 08 '24 Option Exercise 22.95 6,000 137,700 42,608 Jul 10 04:35 PM HIGGINS JOHN L Director May 14 '24 Option Exercise 22.95 4,000 91,800 40,608 May 16 04:17 PM HIGGINS JOHN L Director May 14 '24 Sale 83.84 4,000 335,377 36,608 May 16 04:17 PM Nusse Roeland Director Mar 07 '24 Sale 76.98 10,400 800,627 43,097 Mar 11 04:04 PM
Index RUT P/E - EPS (ttm) -0.62 Insider Own 19.03% Shs Outstand 120.22M Perf Week 0.27%
Market Cap 441.70M Forward P/E - EPS next Y -0.37 Insider Trans -0.80% Shs Float 97.98M Perf Month 14.06%
Income -63.02M PEG - EPS next Q -0.10 Inst Own 53.99% Short Float 8.08% Perf Quarter -1.88%
Sales 20.41M P/S 21.64 EPS this Y -7.60% Inst Trans -0.56% Short Ratio 15.88 Perf Half Y -12.47%
Book/sh 2.43 P/B 1.50 EPS next Y 32.57% ROA -17.43% Short Interest 7.92M Perf Year -34.12%
Cash/sh 0.49 P/C 7.44 EPS next 5Y 23.76% ROE -20.45% 52W Range 3.10 - 6.55 Perf YTD 3.11%
Dividend Est. - P/FCF - EPS past 5Y - ROI -20.21% 52W High -44.26% Beta -0.08
Dividend TTM - Quick Ratio 4.62 Sales past 5Y 13.92% Gross Margin -2.46% 52W Low 17.73% ATR (14) 0.17
Dividend Ex-Date - Current Ratio 4.62 EPS Y/Y TTM -111.80% Oper. Margin -402.81% RSI (14) 53.96 Volatility 6.52% 4.84%
Employees 106 Debt/Eq 0.08 Sales Y/Y TTM -68.45% Profit Margin -308.78% Recom 1.00 Target Price 9.62
Option/Short Yes / Yes LT Debt/Eq 0.07 EPS Q/Q -1.52% Payout - Rel Volume 1.27 Prev Close 3.88
Sales Surprise -50.39% EPS Surprise -16.36% Sales Q/Q -23.83% Earnings Nov 12 AMC Avg Volume 498.69K Price 3.65
SMA20 4.61% SMA50 3.43% SMA200 -10.07% Trades
Volume 635,557 Change -5.93%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-29-23 Initiated RBC Capital Mkts
Outperform
$6
Apr-21-23 Initiated The Benchmark Company
Buy
$8
Apr-13-23 Initiated Craig Hallum
Buy
$10
Feb-22-23 Initiated Cowen
Outperform
$10
Feb-13-23 Initiated H.C. Wainwright
Buy
$11
Dec-20-22 Initiated Truist
Buy
$10
Dec-16-22 Initiated Credit Suisse
Outperform
$13
Nov-29-22 Initiated SVB Leerink
Outperform
$6
Nov-28-22 Initiated Stifel
Buy
$12
Feb-03-25 04:57PM
Dec-16-24 04:15PM
04:15PM
Nov-12-24 04:05PM
Oct-30-24 08:00AM
08:00AM
Loading…
Oct-22-24 08:00AM
Aug-26-24 08:00AM
Aug-08-24 04:05PM
Jul-25-24 08:00AM
Jun-03-24 04:05PM
May-20-24 08:05AM
May-15-24 04:05PM
May-12-24 03:24PM
May-09-24 08:56PM
04:05PM
08:00AM
Loading…
May-01-24 08:00AM
Apr-22-24 08:00AM
Mar-21-24 11:31AM
Mar-20-24 08:54PM
04:05PM
Feb-28-24 08:27AM
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Dec-14-23 04:30PM
Nov-20-23 12:39PM
Nov-14-23 05:03AM
Nov-09-23 05:55PM
09:24AM
08:00AM
Nov-02-23 08:00AM
09:00AM
Loading…
Nov-01-23 09:00AM
Oct-31-23 04:28PM
Oct-26-23 02:32PM
Oct-12-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:20AM
Aug-13-23 08:06AM
Aug-10-23 04:05PM
Aug-07-23 04:05PM
Jul-31-23 08:00AM
Jul-17-23 07:35AM
Jun-13-23 06:00AM
May-18-23 05:09PM
May-17-23 04:05PM
May-16-23 06:06AM
May-14-23 08:03AM
May-11-23 10:55PM
(Thomson Reuters StreetEvents)
+8.36%
07:00AM
May-05-23 07:14AM
May-04-23 06:26AM
May-01-23 08:00AM
Apr-26-23 08:01PM
Apr-25-23 08:00AM
Apr-19-23 08:30AM
Apr-07-23 10:24PM
Apr-05-23 06:09AM
Apr-02-23 08:51AM
Mar-31-23 08:40AM
Mar-30-23 04:05PM
Mar-15-23 11:44AM
Mar-09-23 08:00AM
Mar-08-23 09:53AM
Feb-23-23 07:49AM
Feb-07-23 08:00AM
Feb-01-23 06:56AM
Dec-16-22 12:39PM
Dec-01-22 08:47AM
Nov-15-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 07:00AM
Nov-01-22 04:01PM
04:01PM
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GUSTAFSON KURT A Executive VP, Finance and CFO Feb 16 '25 Option Exercise 0.00 13,541 0 213,466 Feb 19 08:51 PM GUSTAFSON KURT A Executive VP, Finance and CFO Feb 19 '25 Sale 3.67 7,255 26,626 206,211 Feb 19 08:51 PM FOEHR MATTHEW W President and CEO Feb 19 '25 Sale 3.67 19,522 71,646 3,779,160 Feb 19 08:51 PM FOEHR MATTHEW W President and CEO Feb 18 '25 Sale 3.68 13,964 51,388 3,798,682 Feb 19 08:51 PM Berkman Charles S Chief Legal Officer Feb 18 '25 Sale 3.68 8,215 30,231 364,131 Feb 19 08:50 PM Berkman Charles S Chief Legal Officer Feb 19 '25 Sale 3.67 7,255 26,626 356,876 Feb 19 08:50 PM GUSTAFSON KURT A Officer Feb 19 '25 Proposed Sale 3.68 5,188 19,092 Feb 18 08:36 PM FOEHR MATTHEW W Officer Feb 18 '25 Proposed Sale 3.68 13,964 51,390 Feb 18 08:30 PM Berkman Charles S Officer Feb 18 '25 Proposed Sale 3.68 8,215 30,232 Feb 18 08:28 PM Berkman Charles S Chief Legal Officer Jan 21 '25 Sale 3.24 25,489 82,584 343,190 Jan 22 05:41 PM GUSTAFSON KURT A Executive VP, Finance and CFO Jan 21 '25 Sale 3.24 15,526 50,304 212,720 Jan 22 05:40 PM FOEHR MATTHEW W President and CEO Jan 21 '25 Sale 3.24 41,811 135,468 3,749,639 Jan 22 05:40 PM FOEHR MATTHEW W Officer Jan 21 '25 Proposed Sale 3.24 41,811 135,378 Jan 21 07:25 PM Berkman Charles S Officer Jan 21 '25 Proposed Sale 3.24 25,489 82,529 Jan 21 07:24 PM GUSTAFSON KURT A Officer Jan 21 '25 Proposed Sale 3.24 15,526 50,271 Jan 21 07:22 PM Berkman Charles S Chief Legal Officer Dec 09 '24 Sale 4.13 8,022 33,131 323,385 Dec 10 04:47 PM FOEHR MATTHEW W President and CEO Dec 09 '24 Sale 4.13 13,634 56,308 3,714,447 Dec 10 04:44 PM GUSTAFSON KURT A Executive VP, Finance and CFO Dec 09 '24 Sale 4.13 23,871 98,587 200,661 Dec 10 04:41 PM GUSTAFSON KURT A Officer Dec 09 '24 Proposed Sale 4.13 23,871 98,476 Dec 09 08:49 PM FOEHR MATTHEW W Officer Dec 09 '24 Proposed Sale 4.13 13,634 56,245 Dec 09 08:45 PM Berkman Charles S Officer Dec 09 '24 Proposed Sale 4.13 8,022 33,094 Dec 09 08:41 PM FOEHR MATTHEW W President and CEO Nov 25 '24 Option Exercise 3.73 99,434 370,702 3,698,600 Nov 26 04:41 PM Avista Capital Managing Member 10% Owner Jun 29 '24 Option Exercise 3.35 66,668 223,338 15,992,372 Jul 02 05:00 PM FOEHR MATTHEW W President and CEO Jun 27 '24 Option Exercise 3.73 59,659 222,416 3,599,166 Jun 27 04:55 PM FOEHR MATTHEW W President and CEO May 24 '24 Buy 4.42 240,000 1,059,840 3,536,665 May 28 05:55 PM GUSTAFSON KURT A Executive VP, Finance and CFO Apr 08 '24 Sale 5.27 6,954 36,648 176,697 Apr 09 06:38 PM Berkman Charles S Chief Legal Officer Apr 08 '24 Sale 5.27 6,954 36,648 292,617 Apr 09 06:37 PM GUSTAFSON KURT A Executive VP, Finance & CFO Apr 01 '24 Sale 5.46 11,849 64,696 170,110 Apr 02 06:30 PM FOEHR MATTHEW W President and CEO Mar 27 '24 Option Exercise 3.72 243,613 907,023 3,152,416 Mar 29 04:52 PM FOEHR MATTHEW W President and CEO Mar 22 '24 Buy 5.19 225,000 1,167,750 2,908,803 Mar 25 07:07 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
